Melanoma induces, and adenosine suppresses, CXCR3-cognate chemokine production and T-cell infiltration of lungs bearing metastatic-like disease

Cancer Immunology Research

Volumn 3, Issue 8, 2015, Pages 956-967

  Clancy Thompson, Eleanor ^a,b   Perekslis, Thomas J ^a   Croteau, Walburga ^a   Alexander, Matthew P ^a   Chabanet, Tamer B ^a   Turk, Mary Jo ^a   Huang, Yina H ^a   Mullins, David W ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ADENOSINE; CHEMOKINE; CYTOKINE; LIGAND;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; T LYMPHOCYTE; THERAPY EFFECT; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; DISEASE MODEL; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ADENOSINE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA, EXPERIMENTAL; MICE, KNOCKOUT; NEOPLASM METASTASIS; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84962032894     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0015     Document Type: Article

References (37)

1. Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocytemacrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
3. Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, et al. Phase I trial of amelanoma vaccinewith gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001;7:3012-24.
4. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that aremediated bytumor cells. Annu RevImmunol 2007;25:267-96.
5. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
6. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012;72:1070-80.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
8. + Tcell recruitment. Cancer Res 2009;69:3077-85.
9. Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, et al. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother 2010;33:965-74.
10. + T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004;64:7697-701.
11. Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002;20:4549-54.
12. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, et al. Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41:544-52.
13. Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res 2014;2:1044-50.
14. Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011;121:3846-59.
15. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 2012;188:198-205.
16. Nie L, Xiang R, Zhou W, Lu B, Cheng D, Gao J. Attenuation of acute lung inflammation induced by cigarette smoke in CXCR3 knockout mice. Respir Res 2008;9:82.
17. Medoff BD, Wain JC, Seung E, Jackobek R, Means TK, Ginns LC, et al. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol 2006;176:7087-95.
18. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011;89:207-15.
19. + T-cell effector function but not migration. J Virol 2009;83:9486-501.
20. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011;317:620-31.
21. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010;29:5346-58.
22. Wallace KL, Marshall MA, Ramos SI, Lannigan JA, Field JJ, Strieter RM, et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 2009;114:667-76.
23. Hochwald C, Kennedy K, Chang J, Moya F. A randomized, controlled, double-blind trial comparing two loading doses of aminophylline. J Perinatol 2002;134:275-8.
24. Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, et al. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br J Pharmacol 1995;115:1096-102.
25. Kohlmeier JE, Cookenham T, Miller SC, Roberts AD, Christensen JP, Thomsen AR, et al. CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection. J Immunol 2009;183:4378-84.
26. Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8 (+) T cell efficacy. Eur J Immunol 2008;38:2168-79.
27. + T cell trafficking enhances tolerance induction in a mouse model of lung rejection. J Immunol 2011;186:6830-8.
28. Lin Y, Yan H, Xiao Y, Piao H, Xiang R, Jiang L, et al. Attenuation of antigeninduced airway hyperresponsiveness and inflammation in CXCR3 knockout mice. Respir Res 2011;12:123.
29. Barbarroja-Escudero J, Prieto-Martin A, Monserrat-Sanz J, Reyes-Martin E, Diaz-Martin D, Antolin-Amerigo D, et al. Abnormal chemokine receptor profile on circulating T lymphocytes from nonallergic asthma patients. Int Arch Allergy Immunol 2014;164:228-36.
30. Clancy-Thompson E, King LK, Nunnley LD, Mullins IM, Slingluff CL, Mullins DW. Peptide vaccination in montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res 2013;1:332-9.
31. Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated toxoplasma gondii protects against rechallenge. J Immunol 2013;190:469-78.
32. Kang Y-J, Jo J-O, Cho M-K, Yu H-S, Leem S-H, Song KS, et al. Trichinella spiralis infection reduces tumor growth and metastasis of B16-F10 melanoma cells. Vet Parasitol 2013;196:106-13.
33. Valbuena G, Bradford W, Walker DH. Expression analysis of the T-celltargeting chemokines CXCL9 and CXCL10 in mice and humans with endothelial infections caused by rickettsiae of the spotted fever group. Am J Pathol 2003;163:1357-69.
34. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315-23.
35. Erdmann AA, Gao Z-G, Jung U, Foley J, Borenstein T, Jacobson KA, et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005;105:4707-14.
36. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz K-N, et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 2002;119:923-33.
37. Petro M, Kish D, Guryanova OA, Ilyinskaya G, Kondratova A, Fairchild RL, et al. Cutaneous tumors cease CXCL9/Mig production as a result of IFNγ-mediated immunoediting. J Immunol 2013;190:832-41.